Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.

Research Peptide Overview
Retatrutide is an investigational peptide studied for its role as a triple hormone receptor agonist, targeting:
• GLP-1
• GIP
• Glucagon receptors
Retatrutide is not FDA-approved for general clinical use and is intended for research purposes only.
Retatrutide is not FDA-approved for general clinical use and is intended for research purposes only.
30mg
1 in stock
Not for human consumption · Laboratory and research use only · Must be 18+
Research Peptide Overview
Retatrutide is an investigational peptide studied for its role as a triple hormone receptor agonist, targeting:
• GLP-1
• GIP
• Glucagon receptors
Retatrutide is not FDA-approved for general clinical use and is intended for research purposes only.
Significant reductions in body weight
Decreased appetite and caloric intake
Improved metabolic efficiency
Its triple-pathway activity may produce stronger effects than GLP-1-only therapies.
By acting on incretin and glucagon pathways.
Retatrutide may help:
Enhance feelings of fullness
Reduce cravings
Support portion control
Ongoing studies are exploring Retatrutide’s impact on:
Insulin sensitivity
Lipid metabolism
Energy expenditure
Obesity-related metabolic markers
Retatrutide may cause side effects similar to GLP-1-based therapies, including:
Nausea
Vomiting
Diarrhea or constipation
Decreased appetite
Fatigue
Abdominal discomfort
⚠️ Long-term safety is still being evaluated in clinical trials.
Retatrutide is supplied as four prefilled insulin syringes, prepared and ready for injection. Each syringe contains a measured weekly amount for convenience and consistent handling.
❄ Storage & Shipping:
Prefilled syringes are shipped cold to maintain integrity and should be stored refrigerated upon arrival.
Retatrutide is not FDA-approved, informational purposes only.